NEW YORK (GenomeWeb News) – XDx said this week that health insurer Cigna has issued a positive coverage decision for XDx's AlloMap Molecular Expression Testing for potential heart transplant rejection.

The policy, which took effect immediately, applies to about 13.8 million lives covered by Cigna. Barry Kane, senior director of finance and reimbursement at XDx, said the firm is "particularly pleased" that Cigna is formally covering AlloMap for patients six months to five years post-heart transplant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.